BiotechTube
CASI Pharmaceuticals

CASI Pharmaceuticals

CASIPhase 2
casipharmaceuticals.com

CASI Pharmaceuticals is an innovative biopharmaceutical company advancing CID-103, a first-in-class anti-CD38 monoclonal antibody, as a potential treatment for antibody-mediated rejection (AMR) in organ transplant patients and for autoimmune diseases like immune thrombocytopenia (ITP). The company operates globally, with a commercial footprint in China for its oncology products, and is led by an experienced management team with deep expertise in drug development and commercialization. CASI's strategy centers on addressing urgent unmet medical needs in transplantation and autoimmunity through a differentiated mechanism of action that targets persistent plasma cells.

Market Cap
$2.3M
-0.3% period
Pipeline
24
drug candidates
Patents
—
Publications
—

CASI · Stock Price

USD 0.150.00 (-0.33%)

Historical price data

AI Company Overview

CASI Pharmaceuticals is an innovative biopharmaceutical company advancing CID-103, a first-in-class anti-CD38 monoclonal antibody, as a potential treatment for antibody-mediated rejection (AMR) in organ transplant patients and for autoimmune diseases like immune thrombocytopenia (ITP). The company operates globally, with a commercial footprint in China for its oncology products, and is led by an experienced management team with deep expertise in drug development and commercialization. CASI's strategy centers on addressing urgent unmet medical needs in transplantation and autoimmunity through a differentiated mechanism of action that targets persistent plasma cells.

TransplantationAutoimmune DiseasesOncology

Technology Platform

Monoclonal antibody platform targeting CD38, with a focus on a distinct epitope (R78) to reduce red blood cell binding and a dual mechanism depleting plasma cells and NK cells.

Pipeline

24
24 drugs in pipeline
DrugIndicationStageWatch
Melphalan Hydrochloride for InjectionMultiple MyelomaApproved
Panzem® NCDProstate CancerPhase 2
Panzem NCD + TemozolomideRecurrent Glioblastoma MultiformePhase 2
recombinant human Angiostatin protein + paclitaxel + carbopl...Carcinoma, Non-Small-Cell LungPhase 2
2-methoxyestradiolRelapsed Multiple MyelomaPhase 2

Funding History

4
Total raised:$70M
PIPE$25MDec 15, 2020
IPO$15MFeb 15, 2016
Series B$20MJun 15, 2011
Series A$10MJan 15, 2009

Opportunities

The primary growth opportunity is the development and approval of CID-103 for antibody-mediated rejection, a market with no FDA-approved therapies and over 30,000 affected kidney transplant patients in the US alone.
Additionally, expanding the label of CID-103 into large autoimmune disease markets (e.g., ITP) and growing the commercial oncology business in China present significant avenues for revenue growth.

Risk Factors

Key risks include clinical trial failure of the lead asset CID-103, intense competition from repurposed drugs like daratumumab, financial constraints typical of a micro-cap biotech funding late-stage trials, and geopolitical/operational risks associated with its dual US-China business structure.

Competitive Landscape

CASI's main competitor in the anti-CD38 space is Janssen's daratumumab (DARZALEX®), which is being explored off-label in transplantation. CASI differentiates CID-103 through its distinct epitope binding (aiming for a better safety profile) and its focus on developing a subcutaneous formulation for patient convenience in the transplant setting.